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Nanotechnologies are gaining in commercial application. Nanoscale materials are currently 
being used in electronic, magnetic and optoelectronic, biomedical, pharmaceutical, cosmetic, 
energy, catalytic and materials applications. Nano particles as defined are particulate 
dispersions or solid particles with a size in the range of 10-1000nm. Gelatin based 
nanoparticle are prepared because of its biocompatibility and biodegradability. 
Gelatin nanoparticles are a delivery vehicle that could be used to deliver many therapeutics to 
the brain, they will be most effective in delivering drugs that cannot cross the blood-
brain barrier.  In addition, they can be used for drugs of high-toxicity or a short half-life. 
Liposomes are mostly used for drug delivery to the targeted gene. Liposomes increases the 
effective action, availability, absorption of entrapped dietary and nutritional supplements 
which can be used as topical drug delivery system. Stavudine is an analog of thymidine. It is 
phosphorylated by cellular kinases into active triphosphate. The drug we use here is 
Stavudine, which inhibits the HIV reverse transcriptase by competing with natural substrate, 
thymidine triphosphate. It also causes termination of  DNA replication  by incorporating into 
the DNA strand. The drug is dissolved, entrapped, encapsulated or attached to a nanoparticle 
matrix depending upon the method of preparation. The drug Stavudine conjugated with 
liposomes and gelatin NPs can improve the longevity of the HIV patient,leading to a better 
life. 
 
Keywords: Nanotechnology, Nanoparticle, Gelatin, Liposomes, Drug delivery, Anti HIV 
drug Stavudine. 
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Nanotechnology is a rapidly expanding field today due to the multidisciplinary support from  
researchers in the academic, industry, and federal sectors. Nanotechnology advances 
materials with a nano-measurement and gives a few intends to imaginative configuration of 
nano-size medication conveyance frameworks to overcome organic hindrances. (Patil et 
al,2008) These nanoscale particles can be tubular (nanotubes), circular, unpredictably folded, 
and might likewise exist in aggregated forms. Nanoparticles are defined as particulate 
dispersions or solid particles with a size in the range of 10-1000nm. (Iravani et 
al,2014),Nanoparticle products include nanotubes, nanowires, quantum dots and “other” 
nanoparticle. Because of their unique properties Nano crystals (quantum dots) and other 
nanoparticles (gold colloids, Nano bars, dendrimers and Nano shells) have been receiving a 
lot of attention for potential use in Therapeutics, Bioengineering and therapeutics drug 
discovery.   
 
Nanoparticle examination is at present a zone of extreme exploratory enthusiasm because of a 
wide assortment of potential applications in biomedical, optical and electronic fields. (wiki) 
Nanotechnology includes two primary methodologies: (i) the "top-down" methodology, in 
which bigger structures are lessened in size to the nanoscale while keeping up their unique 
properties without nuclear level control (e.g., scaling down in the area of hardware) or 
deconstructed from bigger structures into their littler, composite parts and (ii) the "bottom up" 
methodology, likewise called "atomic nanotechnology" or "sub-atomic assembling," 
presented by (Drexler et al,2005) in which materials are designed from particles or sub-
atomic parts through a methodology of gathering or get toward oneself together . While most 
contemporary innovations depend on the "top-down" methodology, sub-atomic 
nanotechnology holds extraordinary guarantee for leaps forward in materials and assembling, 
gadgets, drug and human services, vitality, biotechnology, data innovation, and national 
security (Sanchez et al,2010 ). 
Nanotechnologies are gaining in commercial application. Nanoscale materials are currently 
being used in electronic, magnetic and optoelectronic, biomedical, pharmaceutical, cosmetic, 
energy, catalytic and materials applications. Areas producing the greatest revenue for 
nanoparticles are reportedly chemical-mechanical polishing, magnetic recording tapes, 
sunscreens, automotive catalyst supports, bio-labelling, electro-conductive coatings and 
optical fibres (Aitken et al,2008). The major goals in designing nanoparticles as a delivery 
system are to control particle size, surface properties and release of pharmacologically active 
agents in order to achieve the site-specific action of the drug at the therapeutically optimal 
rate and dose regimen.[1] The core objective of nanoparticles is to control and manipulate 
bio-macromolecular constructs and supra-molecular  assemblies that are critical to living 
cells in order to improve the quality of human health.  The key advantages of nanoparticles 
are (1) improved bioavailability by enhancing aqueous solubility, (2) increasing resistance 
time in the body (increasing half-life for clearance/increasing specificity for its cognate 
receptors and (3) targeting drug to specific location in the body (its site of action). It is 
increasingly used in different applications, including drug carrier systems and to pass organ 
barriers such as the blood-brain barrier, cell membrane etc. (Shukla et al ,2004 ) 
Nanoparticles overcome the resistance offered by the physiological barriers in the body 
because efficient delivery of drug to various parts of the body is directly affected by particle 
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size. Bioavailability for timed release of drug molecules, and precise drug targeting.  
(Mudshinge et al, 2010) Nanoparticles can be synthesized using various approaches including 
chemical, physical, and biological. Although chemical method of synthesis requires short 
period of time for synthesis of large quantity of nanoparticles, this method requires capping 
agents for size stabilization of the nanoparticles. Nanoparticles have a size range that permits 
them to be infused without blocking needles and vessels and are perfect for targeted drug 
delivery and medicinal imaging because of the pathophysiology of specific issue, for 
example, tumour and irritation (Ozkan et al,2004) 
 
Gelatin based nanoparticle are prepared because of its biocompatibility and biodegradability. 
Gelatin nanoparticles could be laced with medications for delivery to the brain, and that they 
could extend the treatment window for when a drug could be effective. (Elzoghby et al,2013) 
Once administered, the gelatin nanoparticles target damaged brain tissue thanks to an 
abundance of gelatin-munching enzymes produced in injured regions. 
The tiny gelatin particles have a huge benefit. They can be administered nasally, a non-
invasive and direct route to the brain. (Kaul et al,2003) This allows the drug to bypass the 
blood-brain barrier, a biological fence that prevents the vast majority of drugs from entering 
the brain through the bloodstream. Two  major mechanisms  can  be  distinguished  
for addressing  the  desired  sites  for  drug  release:  
(i) passive  and  
(ii) active  targeting. 
The targeted delivery of the medicated nanoparticles can be done with the help of liposomes, 
as carrier. Liposomes are small artificial vesicles of spherical shape that can be created from 
cholesterol and natural nontoxic phospholipids. (Lasic, D. D. ,1995) Due to their size and 
hydrophobic and hydrophilic character(besides biocompatibility), liposomes are promising 
systems for drug delivery. Liposome properties differ considerably with lipid composition, 
surface charge, size, and the method of preparation. (Akbarzadeh et al,2013)  Liposomes can 
be filled with drugs, and used to deliver drugs for 
cancer and other diseases. Some of the advantages of liposome are as follows: 
• Provides selective passive targeting to tumor tissues. 
• Increased efficacy and therapeutic index. 
• Increased stability via encapsulation. 
• Reduction in toxicity of the encapsulated agents. 
• Site avoidance effect. 
• Improved pharmacokinetic effects (reduced elimination, increased circulation life times).  
• Flexibility to couple with site specific ligands to achieve active targeting (Dua et al,2012) 
 
 Liposomes have been used to improve the therapeutic index of new or established drugs by 
modifying drug absorption, reducing metabolism, prolonging biological half-life-or-reducing 
toxicity.  Liposomes have been used to improve the therapeutic index of new or established 
drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or 
reducing toxicity. Liposomes are a form of vesicles  that  consist  either of many, 
few or just one phospholipid bilayers. The polar character of the liposomal core enables  
polar drug molecules to be encapsulated. The  unique ability  of  liposomes  to   entrap drugs  
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both in an aqueous and a lipid  phase  makes  such  delivery  systems  attractive 
for hydrophilic andhydrophobic drugs.Because of advancements in the  methods of preparing 
and formulation liposomes, high‐entrapment efficiencies are possible for incorporating drugs 
into liposomes, creating a tremendous pharmaceutical impact. (Martha, et al,2013) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Department of Life Science, NIT Rourkela  Page 13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF 
LITERATURE 
 
 
Department of Life Science, NIT Rourkela  Page 14 
 
 
 
Nanotechnology is an important field of modern research dealing with design, synthesis, and 
manipulation of particles structure ranging from approximately 1-100 nm in one dimension. 
Remarkable growth in this up-and-coming technology has opened novel fundamental and 
applied frontiers, including the synthesis of nanoscale materials and exploration or utilization 
of their exotic physicochemical and optoelectronic properties. Nanotechnology is rapidly 
gaining importance in a number of areas such as health care, cosmetics, food and feed, 
environmental health, mechanics, optics, biomedical sciences, chemical industries, 
electronics, space industries, drug-gene delivery, energy science, optoelectronics, catalysis, 
reprography, single electron transistors, light emitters, nonlinear optical devices, and photo 
electrochemical applications. (Lisziewicz et al,2013) 
Late advances in the use of nanotechnology in drug, regularly alluded to as nano-medicine, 
may reform our way to deal with social insurance. Nanotechnology includes making and 
using the builds of variable science and construction modeling with measurements at the 
nanoscale level similar to those of biomolecules or natural vesicles in the human body. 
Working with sub molecular cooperation’s, it offers the potential for exceptional and novel 
methodologies with a wide range of utilizations in tumor treatment including zones, for 
example, diagnostics, therapeutics, and prognostics. Nanotechnology is characterized as the 
study and utilization of structures between 1 nanometer and 100 nanometers in size. 
Nanotechnology is the collaboration of mechanical, electrical, substance designing, material 
sciences, microelectronics, and natural screening. (Patil et al,2008) Nanotechnology 
additionally opens pathways to growing new and effective remedial ways to deal with growth 
treatment that can beat various obstructions postured by the human body contrasted with 
customary methodologies.  (Kim E., et al,2013) The field of “Nano medicine” is the science 
and technology of diagnosing, treating,  and preventing disease and traumatic injury, of 
relieving pain, and of preserving and improving human health, using nanoscale structured 
materials, biotechnology, and genetic engineering, and eventually complex machine systems 
and nonorobots. (De Jong et al,2008) Nanomedicine involves the utilization of 
nanotechnology for the benefit of human health and well- The emergence of nanotechnology 
at the interface between biology, chemistry, physics and engineering has spawned new 
opportunities for a wide range of applications such as targeted drug delivery and controlled 
release,1 protein and DNA sensing, tissue engineering, and sensing-based early diagnostic 
and biomedical imaging. (Lisziewicz et al,2013) 
 
Applications:  
Nanotechnology is helping to considerably improve, even revolutionize, many technology 
and industrial sectors: energy, environmental science, information technology, medicine, 
homeland security, food safety, and transportation, among many other. Nanotechnology have 
various applications in various fields like physics, chemistry, medical, environment etc. 
 
Application of nanotechnology in environmental science:  
Nanotechnology helps to increase the efficiency of fuel production from normal to lower 
grade materials. It also help meet the need for , clean drinking water through rapid, low cost 
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detection of impurities in and filtration and purification of water. Bacterial identification and 
elimination in which nano carbohydrate particles bind with bacteria so they can be detected 
and eliminated is used to minimize and enhance the environmental sustainability of process 
currently producing negative externalities. Increasing the efficiency of energy production or it 
could lead to a strong reduction of energy consumption for illumination by nanotechnology 
(Robert A. Freitas Jr. 1999). 
 
Application of nanotechnology in medical science:  
Nanotechnology is widely used for drug delivery, gene therapy, detection of disease causing 
organism, diagnosis, etc. Nanotechnology is used to treat cancer by involving targeted 
chemotherapy that delivers a tumor killing agent called tumor necrosis factor alpha(TNF) 
which is attached with gold nanoparticles, nanotechnology is also used for imaging and 
detection of diseases (Gunasekera A, 2009). The use of nanotechnology in these areas of 
medicine is one broken bones and for cell reparation can lead to better and faster healing of 
the body. Nanotechnology in medicine involves applications of nanoparticles currently under 
development, as well as longer range research that involves the use of manufactured nano-
robots to make repairs at the cellular level. 
 
 
NANOPARTICLE: 
Nanoparticles have been receiving a lot of attention recently and their utilization is becoming 
a growing industry. "Nano" is derived from the Greek word νᾶνος (nanos) for dwarf person. 
A nanometre is a billionth of a meter, that is, around 1/80,000 of the width of a human hair, 
or 10 times the width of a hydrogen atom. Nanoparticles are particles between 1 and 100 
nanometres in size.  Nanoparticles have a greater surface area per weight than larger particles 
which causes them to be more reactive to some other molecules. At the point when the 
physicist and Nobel laureate Richard Feynman tested the science group to think little in his 
1959 address 'There's Plenty of Room at the Bottom', he planted the seeds of another period in 
science and innovation that is today's Nanotechnology. Nano-particle usually forms the core 
of nano-biomaterial. It can be used as a convenient surface for molecular assembly, and may 
be composed of inorganic or polymeric materials. (Nesalin et al,2013) It can also be in the 
form of nano-vesicle surrounded by a membrane or a layer. The shape is more often spherical 
but cylindrical, plate-like and other shapes are possible. Due to their size features and 
advantages over available chemical imaging drug agents and drugs, inorganic particles have 
been examined as potential tools for medical imaging as well as for treating diseases. 
Inorganic nonmaterial have been widely used for cellular delivery due to their versatile 
features like wide availability, rich functionality, good compatibility, and capability of 
targeted drug delivery and controlled release of drugs  The size and size distribution might be 
important in some cases, for example if penetration through a pore structure of a cellular 
membrane is required. Nanoparticles fall into three major types: 
 Naturally occurring 
 Incidental 
 Engineered 
 
 
Department of Life Science, NIT Rourkela  Page 16 
 
Naturally occurring nanoparticles include Sea spray, mmineral composite, vvolcanic ash, 
viruses. A result of man-made industrial processes, incidental nanoparticles includes Cooking 
smoke, Diesel exhaust, Welding fumes, Industrial effluents, and Sandblasting. Engineered 
nanoparticles comprise of any manufactured particles with nanoscale dimensions which 
include Metals, Quantum dots, Bucky balls/nanotubes, Sunscreen pigments, Nanocapsules. 
Nanoparticles are classified based on their dimensions. (Mihrimah et al,2004) 
i) In one dimension: One-dimensional systems, such as thin films or 
Manufactured surfaces or coatings are one dimensional nanomaterial’s.. Their applications 
include corrosion resistant ,wear and scratch resistant, hydrophobic and self-cleaning ,dirt 
repellent, antibacterial and antimicrobial, catalytically active and chemically functionalized 
and transparency modulated surfaces. 
ii) In two dimension: Nanotubes, nanowires, nano-fibers and nano-polymers are two 
dimensional nanoparticles. 
 
SYNTHESIS: 
There are two methods or approaches for synthesis of nanoparticles which includes physical 
approaches and chemical approaches.  
 
 Physical approaches:  
Various metal nanoparticles such as silver, gold, sulphide, lead and cadmium are 
synthesised by physical approaches which includes evaporation-condensation and 
laser ablation. Evaporation-condensation method is mostly used for synthesis of 
nanoparticles as compared to laser ablation methods. This method uses tube furnace at 
atmospheric pressure. And this furnace tube require power consumption more than 
several kilowatts and a preheating time of several of tens of minute to reach a stable 
operating temperature.(Kruis et al., 2000: Magnusson et al., 1999). Physical methods 
are useful as nanoparticles generators for long terms experiments.  
 
 Chemical approaches: 
Most common approach for synthesis of nanoparticles is chemical reduction by 
organic and inorganic reducing agents. Sodium citrate, ascorbate, polyol process, 
tollens reagent, elemental hydrogen, etc. are the most common reducing agents. In 
this method it is important to use protective agent to stabilize dispersive nanoparticles 
during the course of metal nanoparticle preparation and protect the nanoparticles that 
can be absorbed on or bind onto nanoparticle surfaces and avoiding their 
agglomeration (Oliveira et al., 2005).  
 
USES- 
Nanoparticles are mostly used in drug delivery systems like chemotherapy drugs directly to 
treat cancerous cell, gene delivery in gene therapy, detection of proteins, destruction of 
tumours with drugs or heat or biological detection of disease causing organism and diagnosis. 
Sometime nanoparticles are also used in probing of DNA structure. Nanoparticles of carbons 
are used for developing low cost electrodes for fuel cells. These electrodes may be able to 
replace the expensive platinum needed for fuel cell catalysts. Nanoparticles are used in 
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labelling of bio-molecules such as antigen, antibody, DNA. Main function provided by 
nanoparticles is immobilisation of bio-molecules (Katz et al., 2004). Nanotechnology is also 
used in manipulation of cells and bio-molecules. 
 
GELATIN NANOPARTICLE: 
With regards to nanoparticles based on synthetic polymers, polylactide (PLA),polyglycolide 
(PLG), and poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles represent the most 
extensively investigated ones (Panyam & Labhasetwar 2003).  In addition to these polymers, 
natural biopolymers and macromolecules such as chitosan (Janes et al. 2001), sodium 
alginate (Rajaonarivony et al. 1993), albumin (Kreuter 1978), collagen (Lee et al. 2001) and 
gelatin represent a second fundamental class of base materials for nanoparticles. Among 
these, nanoparticles of proteinaceous origin, e.g albumin, collagen and gelatin have raised 
specific interest. In the present work, gelatin nanoparticles have been chosen as promising 
drug delivery system candidate. Typically, this natural biopolymer is present in other fields of 
our daily life. Gelatin is a translucent, colourless, brittle (when dry), flavourless foodstuff, 
derived from collagen obtained from various animal by-products. Gelatin is one of the protein 
materials that can be used for the production of Nano particles. It’s derived by hydrolytic 
degradation of collagen, the principle component of animal connective tissue. Gelatin has 
found application in food, photographic, cosmetic and pharmaceutical industries over the 
years. Recently, its usage as colloid stabilizer, foaming agent and emulsifiers. The source and 
type of collagen will influence the properties of the resulting gelatin. The main raw material 
for gelatin production is skin and bones from bone and porcine source. 
During hydrolysis, the natural molecular bonds between individual collagen strands are 
broken down into a form that rearranges more easily. Its chemical composition is, in many 
respects, closely similar to that of its parent collagen. The amount of gelatin being applied in 
pharmaceutical industry is not negligible, as far as capsules and ointments are concerned 
(Djagny et al. 2001). But also for current research in fields of delivery vehicles for the 
controlled release of biomolecules such as proteins and nucleotides, gelatin has generated 
increased interest (Young et al. 2005). While gelatin and the delivery systems based on this 
polymer are biocompatible and biodegradable without toxic degradation products (Ward et 
al. 1977). 
 
PROPERTIES: 
Gelatin is biodegradable and bio compatibility in physiological environments. These 
characteristics have contributed to selections proven record of safety as a plasma expander, as 
an ingredient in drug formulations, and as a sealant for vascular prosthesis. Although to date 
up to 27 different types of collagen have been identified type I collagen is the most occurring 
collagen in connective tissue. Gelatins qualify for a particular application depends largely on 
its rheological properties. Apart from basic physio chemical properties such as composition 
parameters, solubility, transparency color, odor and taste, the main attributes that best define 
the overall commercial quality of gelatin one gel strength and thermal physical properties of 
gelatin influence its quality and potential application since they are related to gelatin 
structure. 
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SOURCE OF GELATIN : 
 
The most abundant sources of gelatin one pig skin (46%), bovine hide, (29.4%) pork and 
cattle bones (23.1%). Due to their availability, animal skins and bones have been used 
extensive as a source of raw material for the formulation of the shell of gelatin capsules. 
Their excellent film forming ability and mechanical stability properties of gelatin result in the 
desired physical properties. Furthermore they can be recycled and retain their good 
performance. The gelatin made from the traditional material like animal skin, bone, tendon 
and collagen have been noted to meet the necessary pharmaceutical requirements as being 
quickly hydrolyzed by gastrointestinal enzymes. In addition they contain a variety of 
nutritious amino acids. The purified products obtained therefore are easily swallowed and 
rapidly absorbed. 
 
TYPES OF GELATIN : 
According to origin and pretreatment of the utilized collagen, two major types of gelatin are 
commercially produced (Fig. 1). Gelatin type A (acid) is obtained from porcine skin with 
acidic pre-treatment prior to the extraction process. The second prevalent gelatin species, type 
B (basic), is extracted from ossein and cut hide split from bovine origin. Thereby, an alkaline 
process, also known as “liming” is applied. (Vandervoort et al,2004) 
 
 
 
Fig-1: Preparative process for acidic and basic gelatins from collagen (Tabata & Ikada 
1998) 
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Gelatin is a polyampholyte having both cationic and anionic along with hydrophobic groups 
present in the approximate ratio 1:1:1, which makes this polypeptide special. The gelatin 
molecule is ~13% positively charged (lysine and arginine), ~12% negatively charged 
(glutamic and aspartic acid) and ~11% of the chain hydrophobic in nature (comprising 
leucine, isoleucine, methionine and valine.) 
 
 
PREPARATION OF GNPs- 
 
1. Desolvation: 
Desolvation technique is based on the addition of a desolvating agent (e.g., alcohol or 
acetone) to an aqueous gelatin solution in order to dehydrate the gelatin molecules resulting 
in conformational change from stretched to coil conformation. Next, to harden the native 
particles, a step of crosslinking is required. However, the use of native gelatin produces large 
particles with a wide size range due to heterogeneity in molecular weight of gelatin. Addition 
of a second desolvation step by (Coester et al,2000) has been shown to be more efficient in 
the formation of smaller and uniform nanoparticles. 
100g gelatin was dissolved in distilled water (10ml) under constant heating at 40±1ºC. 
Acetone (10ml) was added to the gelatin solution as a desolvation agent to precipitate the 
high molecular weight (HMW) gelatin. The supernatant was discarded, and the HMW gelatin 
was re dissolved by adding distilled water (10ml) with stirring at 600rpm under constant 
heating. The pH of the gelatin solution at the second desolvation step was adjusted at pH 8 
drop wise addition of acetone (30ml) to form GNPs. At the end of the process, glutraldehyde 
solution (25% V/V aqueous solution) was added 2 µl. It act as a cross linking agent, and the 
solution was stirred for 12 hours at 600rpm. Effect of parameters like pH, temperature, 
amount of glutaraldehyde (cross-linker) was studied.Crosslinking of GNPs is required to give 
gelatin stability, shape andan enhanced circulation time in vivo as compared to uncrosslinked 
particles. GNPs prepared without crosslinking were found to be unstable and tended to 
aggregate upon aging. 
 
 
2. Emulsification-solvent evaporation 
In this technique, GNPs (100 to 400 nm) were prepared adopting a solvent evaporation 
method based on a single W/O emulsion. Briefly, a pre warmed 
gelatin solution containing insulin was added dropwise to poloxamer solution under stirring 
to form an emulsion which was then cooled to 5 °C to promote nanoparticle formation 
followed by crosslinking. 
 
3. Coacervation-phase separation 
Coacervation is a process during which a homogeneous solution of charged macromolecules 
undergoes liquid–liquid phase separation, giving rise to a polymer rich dense phase at the 
bottom and a transparent solution. The addition of natural salt or alcohol normally promotes 
coacervation that resulted in desired nanoparticles. GNPs were successfully prepared by slow 
addition of sodium sulfate to aqueous gelatin solution containing surfactant (Tween 20) 
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followed by addition of isopropanol to dissolve the precipitate by sodium sulfate. A second 
aliquot of sodium sulfate was added until the solution turned turbid, which indicated the 
formation of gelatin aggregates. Distilled water was then added until the solution turned clear 
and glutaraldehyde was added to crosslink GNPs. 
 
WHY GELATIN? 
Gelatin nanoparticles could be laced with medications for delivery to the brain, and that they 
could extend the treatment window for when a drug could be effective. Gelatin is 
biocompatible, biodegradable, and classified as "Generally Recognized as Safe" by the Food 
and Drug Administration. Once administered, the gelatin nanoparticles target damaged brain 
tissue thanks to an abundance of gelatin-munching enzymes produced in injured regions. The 
tiny gelatin particles have a huge benefit. (Kaul et al,2004) They can be administered nasally, 
a noninvasive and direct route to the brain. This allows the drug to bypass the blood-brain 
barrier, a biological fence that prevents the vast majority of drugs from entering the brain 
through the bloodstream. Gelatin nanoparticles, administered through the nasal cavity, can 
help deliver other drugs to more effectively treat a variety of brain injuries and neurological 
diseases.(Elzoghby-et-al,2013) 
"Gelatin nanoparticles are a delivery vehicle that could be used to deliver many therapeutics 
to the brain, they will be most effective in delivering drugs that cannot cross the blood-
brain barrier.  In addition, they can be used for drugs of high-toxicity or a short half-life. 
 
LIPOSOMES- 
 
 
Liposomes are spherical, self closed vesicles of colloidal dimensions, in which phospho-lipid 
bilayer  part of the solvent, in which they freely float, into their interior (Bangham et al., 
1964). The name liposome is derived from two Greek words: “lipo” meaning fat and “soma”  
which means body. Liposomes are the simple spherical  microscopic vesicles. Liposomes are 
a form of nanoparticle which is formed by using lecithin. It can be prepared by disrupting 
biological membrane or by sonication. Liposomes can be made entirely from naturally 
occurring substances and are therefore nontoxic, biodegradable and non immunogenic. In 
1961, liposomes were first described by British haematologist Dr. Alec D Bangham FRS, at 
the Babraham Institute , in Cambridge.  
 
TYPES- 
Liposomes can be classified on the based on the following parameters: 
i. Structural parameter,  
ii. Method of preparation  
iii. Composition and  
iv. Applications.  
 
 On the basis of structural parameter the liposomes are classified into 4 types- 
multilamellar vesicles, oligolamellar vesicles, unilamellar vesicle. Multilamellar 
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vesicles are less than 0.5μm (>0.5μm) in size. Oligolamellar vesicles ranges between 
0.1 to 1.0μm in size. Unilamellar vesicles are divided into two types which includes 
small unilamellar vesicles and large unilamellar vesicles. Small unilamellar vesicles 
range between 20 to 100nm. Large unilamellar vesicles ranges between greater than 
100nm (>100nm) (Dua et al., 2012). 
 
 Liposome are classified on the basis of method of preparation which includes 
Dehydration- rehydration methods. Unilamellar vesicles made by reverse phase 
evaporation method, multilamellar vesicles made by reverse phase evaporation, 
vesicles made by extrusion technique, frozen and thawed multilamellar vesicles and 
stable pluri-lamellar vesicles( Dua et al., 2012).  
 On the basis of composition and application liposomes are classified into 
conventional liposomes these are negatively or neutral charged phospholipids and 
cholesterols, fusogenic liposome, pH sensitive liposome, cationic liposome, long 
circulatory liposome and immune-liposomes these are attached with monoclonal 
antibodies. (Dua et al., 2012). 
 
USES: 
Liposome has its own value in different fields. Liposomes are mostly used for drug delivery 
to targeted gene. Liposomes are also used in mathematics for topology in two dimensional 
surfaces in three dimensional surface governed only by bi-lipid elasticity. In biophysics 
liposomes are used for checking of the aggregation behaviour and fractal strength of 
materials. In chemistry liposomes are also used for micro compartilization. In 
pharmaceuticals it is used for studies of drug actions (Lipowsky and Sackmann, 1995). 
Liposomes as drug delivery vehicles in medicine, adjuvants in case of vaccination, signal 
enhancers in medical diagnostics , solubilizers for various ingredients as well as support 
matrix for various ingredients and penetration carriers in cosmetics (Lassic et al., 1992). 
Liposomes containing membrane anchored by chelating agents can be used to clean toxic or 
radioactive metals from solutions. (Lassic., 1993). Liposomes increases the effective action, 
availability, absorption of entrapped dietary and nutritional supplements which can be used as 
topical drug delivery system (George et al., 1975). But liposomal drug delivery system has 
certain shortcomings like the need for modification for site specific or organ specific drug 
delivery, high production cost, leakage and incorporation of encapsulated drug/molecule. The 
unfavourable reactions  like oxidation and hydrolysis of phospholipids reduces the half life of 
the formulation, solubility decreases and  there is incipient stability of drug in the medium 
(Sirisha.V.N et al., 2012). 
 
 
STAVUDINE: 
The human immunodeficiency virus (HIV) is retrovirus that causes the acquired 
immunodeficiency syndrome (AIDS),  a condition in humans in which progressive failure of 
the immune system allows life-threatening opportunistic infections.( Garg, Minakshi, et 
al,2006) HIV and AIDS have emerged as being amongst the most serious and challenging 
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public health problems in the world. It is composed of two copies of positive single-
stranded RNA that codes for the virus's nine genes enclosed by a conical capsid composed of  
2,000 copies of the viral protein p24. The single-stranded RNA is tightly bound to nucleo 
capsid proteins, p7, and enzymes needed for the development of the virion such as reverse 
transriptase, proteases, ribonuclease and integrase. It is  surrounded by the viral envelope that 
is composed of two layers of fatty molecules called phospholipids taken from the membrane 
of a human cell when a newly formed virus particle buds from the cell. HIV infects vital cells 
in the human immune system such as helper T cells, macrophages, and dendritic cells. HIV 
disrupts the body’s natural disease-fighting mechanisms, which makes it particularly deadly 
and complicates efforts to develop a vaccine against it. Like all viruses, HIV gets inside 
individual cells in the body and highjacks their machinery to make thousands of copies of 
itself. HIV replication is especially hard for the body to control because the white blood cells 
it infects, and eventually kills, are a critical part of the immune system. Additionally, when 
HIV copies its genes, it does it sloppily. This causes it to quickly mutate into many different 
strains. As a result, the virus easily outwits the body’s immune defenses, eventually throwing 
the immune system into disarray. HIV infection leads to low levels of CD4 T cells through a 
number of mechanisms, including  apoptosis of uninfected bystander cells, direct viral killing 
of infected cells, and killing of infected CD4
+
 T cells by CD8 that recognize infected cells. 
When CD4
+
 T cell numbers decline below a critical level, cell mediated immunity is lost, and 
the body becomes progressively more susceptible to opportunistic infections.  
There are two species of HIV namely, HIV 1 and HIV 2 with their respective subspecies. 
HIV-1 is the global common infection whereas the latter is restricted to mainly West Africa. 
Infection with HIV occurs by the transfer of  blood, semen, vaginal fluid, pre-ejaculate, 
or breast milk.  HIV infection in the human body results mainly from the integration of the 
viral genome into the host cell for the purpose of cell replication. (Spreen et al,2013) 
The current clinical therapy, known as highly active antiretroviral treatment (HAART), is 
considered as one of the most significant advances in the field of HIV therapy. HAART is 
a lifelong necessity and any non-compliance leads to a rapid increase in the viral load. The 
reason for this relapse is related to the poor targeting ability of the antiretroviral agent to 
the latent sites of infection. (Iannazzo, D., et al. ,2015) Major limitation of the current HIV 
treatment is linked to the short residence time and resulting low concentration of 
antiretroviral drugs at certain inaccessible viral reservoir sites such as lymphatic system, 
macrophages, lymphocyte, central nervous system (CNS) and lungs. [Sharma et al]. 
Stavudine (2′,3′-didehydro-2′,3′-dideoxythymidine, d4T, brand name Zerit) is a nucleoside 
analog reverse-transcriptase inhibitor(NARTI) active against HIV.(wiki) Stavudine is 
an analog of thymidine. It is phosphorylated by cellular kinases into active triphosphate. 
Stavudine triphosphate inhibits the HIV reverse transcriptase by competing with natural 
substrate, thymidine triphosphate. It also causes termination of  DNA replication  by 
incorporating into the DNA strand. (Shegokar et al,2011) Stavudine is an oral medication 
that is used for the treatment of infections with the human immunodeficiency virus (HIV). 
It is in a class of drugs called reverse transcriptase inhibitors which also includes 
zalcitabine (Hivid) , zidovudine (Retrovir) , didanosine (Videx) , and  lamivudine (Epivir). 
During infection with HIV, the HIV virus multiplies within the body's cells. The newly 
formed viruses are released from the cells and spread throughout the body where they 
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infect other cells. In this manner the infection continually spreads to new uninfected cells 
that the body is continually producing, perpetuating HIV infection. (Marco, et at ,2013) 
When producing new viruses, the HIV virus must manufacture new DNA for each virus. 
Reverse transcriptase is the enzyme that the virus uses to form this new DNA. Specifically, 
stavudine is converted within the body to its active form (stavudine triphosphate). 
(Sandhya et al,2014) This active form is similar to thymidine triphosphate, a chemical that 
is used by the HIV virus to make new DNA. (Dinesh, et al,2013) The reverse 
transcriptase uses stavudine triphosphate instead of thymidine triphosphate for making 
DNA, and the stavudine triphosphate interferes with the action of the reverse transcriptase. 
Although it has an effect on the HIV virus, but there are also several side effects of this 
drug Stavudine in the brand name of ZERIT which have side effects like that of , nausea, 
vomiting, abdominal pain, diarrhea, unexpected weight loss unexpected tiredness,muscle 
pain, feeling cold especially in the arms and legs , dizziness etc. [Minakshi et al] 
 
NANOPARTICLES FOR DRUG DELIVERY: 
Drug delivery is the method or process of administering a pharmaceutical compound to 
achieve a therapeutic effect in humans or animals. For the treatment of human diseases, nasal 
and pulmonary routes of drug delivery are gaining increasing importance. (Lisziewicz et 
al,2013) These routes provide promising alternatives to parenteral drug delivery particularly 
for peptide and protein therapeutics. For this purpose, several drug delivery systems have 
been formulated and are being investigated for nasal and pulmonary delivery. (Nagpal et 
al,2014) These include liposomes, proliposomes, microspheres, gels, prodrugs, cyclodextrins, 
among others. (Raveen, et al.,2014) Nanoparticles composed of biodegradable polymers 
show assurance in fulfilling the stringent requirements placed on these delivery systems, such 
as ability to be transferred into an aerosol, stability against forces generated during 
aerosolization, biocompatibility, targeting of specific sites or cell populations in the lung, 
release of the drug in a predetermined manner, and degradation within an acceptable period 
of time. (Gaurav, et al,2012) 
Nano particles as defined are particulate dispersions or solid particles with a size in the range 
of 10-1000nm. The drug is dissolved, entrapped, encapsulated or attached to a nanoparticle 
matrix depending upon the method of preparation, nanoparticles, (André, et al.,2014) Nano 
spheres or Nano capsules can be obtained. The major goals in designing, Nano particles as a 
delivery system and to control particle size, Surface properties and release of 
pharmacologically agents in order to achieve the site- specific action of the drug at the 
therapeutically optimal rate and dose regimen. (Feng at al,2014) 
The advantages of using nanoparticles as a drug delivery system includes the following 
* Manipulated to achieve both passive and active drug targeting after parental-administration. 
* They control and sustain release of the drug during the transportation and at the site of 
localization, altering organ distribution of the drug so as to achieve increase in drug therapeutic 
efficacy and reduction in side effects. 
* Controlled release and particle degradation characteristics can be readily modulated by the choice 
of matrix constituents. 
* Site specific targeting can be achieved by attaching targeting ligands to surface of particles or use 
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of magnetic guidance. 
* The system can be used for various routes of administration including oral, nasal, parental, 
intraocular etc.  ( Jong Yuh, et al,2013) 
Nanoparticles can be prepared from a variety of materials such as proteins, polysaccharides and 
synthetic polymers. The selection of matrix materials is dependent on many features including Size 
of nanoparticles required, Inherent properties of the drug, e.g. aqueous solubility and stability, 
Surface characteristics such as charge and permeability, Degree of biodegradability, bio compatibility 
and toxicity,drug release profile desired and antigenicity of the final product. Among the available 
potential colloidal drug carrier systems covering the size range described, protein based 
nanoparticles play an important role. (Gomes et al,2014) Most often serum albumin obtained from 
human, bovine, legumin, etc., as well as gelatin was used as the starting material for the 
preparations. (De Jong et al,2008) 
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MATERIALS AND 
METHODS 
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1. Glassware and Apparatus  
All glass wares such as measuring cylinders, beakers, conical flasks, funnel, test tubes, 96 
well plate, petriplates, filter paper (Whatman 40), eppendorf tubes, and microfuge tips 
etc. were purchased from Borosil, India. 
 
 
2. Chemicals Required:  
The drug Stavudine was obtained under the brand name ZERIT from Hindustan Latex 
Limited(HLL),Thiruvanthapuram. Glutaral dehyde, Gelatin, Soya- lecithin, Ethanol 
and Acetone, Nutrient Agar and Nutrient Broth media were purchased from Hi-media 
Pvt. Ltd Mumbai, India. Distilled water and all other chemicals and solvents used in 
our work were of analytical grade and available in Department of Life Science, NIT 
Rourkela. 
 
 
3. Instruments Used:  
The basic instruments used for the preparation and characterization of the samples 
like Weighing balance (Sartorius), Magnetic stirrer (Remi), Probe Sonicator 
(Plexiglas), Refrigerated centrifuge (Eppendrof), Spectrophotometer (UV Lambda 
35(R)(Perkin Elmer), FTIR( ) , ZETA Sizer Nanoseries , (Malvern instrument Nano 
Zs ), Rotary evaporator ( ) was available in the Department of Life Science, NIT 
Rourkela.  
Specialized facilities like X-Ray Difraction, Scanning Electron Microscopy, , Particle 
Size Analyzer and kindly allowed by the Dept. of Physics, Dept. of Metallurgical & 
Materials Engineering (MM), Dept. of Ceramic Engineering (CR) and Dept. of 
Chemistry (CY) respectively of NIT Rourkela.  
 
SAMPLE PREPARATION AND CHARACTERIZATION: 
 
1. Preparation Of Blank Gelatin Nanoparticles: 
 
a.  
 
Fig 2: Gelatin powder 
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100g gelatin was dissolved in distilled water (10ml) under constant heating at 40±1ºC. 
Acetone (10ml) was added to the gelatin solution as a desolvation agent to precipitate 
the high molecular weight (HMW) gelatin. The supernatant was discarded, and the 
HMW gelatin was re dissolved by adding distilled water (10ml) with stirring at 
600rpm under constant heating. The pH of the gelatin solution at the second 
desolvation step was adjusted at pH 8 drop wise addition of acetone (30ml) to form 
GNPs. At the end of the process, glutraldehyde solution (25% V/V aqueous solution) 
was added 2 µl. It act as a cross linking agent, and the solution was stirred for 12 
hours at 600rpm. Effect of parameters like pH, temperature, amount of glutaraldehyde 
(cross-linker) was studied. 
 
 
 
2. Preparation Of Drug (Stavudine) loaded Gelatin Nanoparticles:  
 
 
 
100g gelatin was dissolved in distilled water (10ml) under constant heating at 40±1ºC. 
Acetone (10ml) was added to the gelatin solution as a desolvation agent to precipitate 
the high molecular weight (HMW) gelatin. The supernatant was discarded, and the 
HMW gelatin was re dissolved by adding distilled water (10ml) with stirring at 
600rpm under constant heating. The pH of the gelatin solution at the second 
desolvation step was adjusted at pH 8 drop wise addition of acetone (30ml) to form 
GNPs . Drug was added dropwise.This method was repeated several times but by 
varying the drug concentration each time. At the end of the process, glutraldehyde 
solution (25% V/V aqueous solution) was added 2 µl. It act as a cross linking agent, 
and the solution was stirred for 12 hours at 600rpm. Different concentration of drug 
loaded nanoparticles were prepared in the ratio of 1:2 (50mg drug), 1:4 (25mg drug), 
1:10(10mg drug) and 1:20(5mg drug). 
 
 
 
Fig 3: Drug- STAVUDINE 
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3. Preparation of blank liposomes : 
c.         
 
Liposomes were prepared by Reverse phase evaporation method as described by 
____________. Soya Lecithin (0.6g) was dissolved in 10 ml of ethanol. This mix was 
stirred in a closed vessel at 700rpm till a clear solution was obtained. The solution 
was then subjected to Rotary evaporator at  41ºC till a thin layer was formed. The thin 
layer was then again redehydrated by adding water to it. The rehydrated solution so 
obtained was now centrifuged. The supernatant was discarded and the pellet so 
obtained was lyophilized and stored. 
 
4. Preparation of liposomes with Drug Loaded GNPS: 
Liposomes were prepared by Reverse phase evaporation method. Soya Lecithin (0.6g) 
was dissolved in 10 ml of ethanol along with different formulations of GNPs i.e., 
1:2(50mg drug), 1:4(25mg drug), 1:10 (10mg drug), 1:20(5mg drug).This mix was 
stirred in a closed vessel at 700rpm till a clear solution was obtained. The solution 
was then subjected to Rotary evaporator at  41ºC till a thin layer was formed. The thin 
layer was then again rehydrated by adding water to it. The rehydrated solution so 
obtained was now centrifuged. The supernatant was discarded and the pellet so 
obtained was lyophilized and stored. 
 
CHARACTERIZATION OF DRUG LOADED GELATIN 
NANOPARTICLES AND LIPOSOMES: 
 
1. SEM (scanning electron microscope) Analysis:   
To study vesicle shape or morphology of Gelatin Nanoparticles  can be done by using 
scanning electron microscope. Gelatin Nanoparticles were visualised using Jeol 6480 
LVJSM electron microscope. For SEM one drop of Gelatin Nanoparticles were 
mounted on a stub covered with clean glass respectively. The drop was spread out on 
the glass homogenously. A sputter coater was used to sputter coat the samples with 
Fig 4: Soy lecithin powder 
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platinium and samples were examined under Jeol 6480 LVJSM at an accelerating 
voltage 20kv. 
 
2. XRD Analysis: 
The phase variety and grain size of synthesized drug loaded gelatin nanoparticles was 
determined by X-ray diffraction spectroscopy (Regaku,Japan). The synthesized silver 
nanoparticles were studies with CUKα radiation at voltage of 30 kV and current of 20 
MA with scan rate of 0.030/s. Different phases present in the synthesized samples 
were determined by X′ pert high score software with search and match facility. The 
particle size of the prepared samples were determined by using Scherrer′s equation as 
follows:   
                                                   𝐷≈0.9𝝀/𝛽cosθ 
Where D is the crystal size, λ is the wavelength of X-ray, Ѳ is the Braggs angle in 
radians and B is the full width at half maximum of the peak in radians. 
 
3. ATR-FTIR analysis: 
The chemical composition of the synthesized drug loaded nanoparticles and gelatin-
stavudine conjugated liposomes was studied by using FTIR spectrometer (Bruker-
alpha). The solutions were characterized in the range 4000–400 cm-1. 
 
4. DLS & Zeta-Potential Analysis: 
Dynamic light scattering (DLS) which is based on the laser diffraction method with 
multiple scattering techniques was employed to study the average particle size of drug 
loaded gelatin nanoparticles and gelatin-stavudine conjugated nanoparticles.. The 
prepared sample was dispersed in deionised water followed by ultra-sonication. Then 
solution was filtered and centrifuged for 15 min.at 25ºC with 5000 rpm and the 
supernatant was collected. The supernatant was diluted for 4 to 5 times and then the 
particle distribution in liquid was studied in a computer controlled particle size 
analyzer (ZETA sizer Nanoseries,Malvern instrument Nano Zs). 
 
 
5. Determination of drug encapsulating capacity:  
Determination of drug encapsulating capacity of  Drug loaded Gelatin NPs and 
liposomes can be determined by ultracentrifugation method Vesicular preparation 
containing stavudine  is kept overnight at 4ᵒC and centrifuge in ultra centrifugation 
4ᵒC at 30,000 rpm for 2 hrs. Stavudine is assayed in both sediment and supernatant at 
OD of 254nm. The entrapment efficiency is calculated using following formula: 
 
 
 
%entrapment efficiency= Amount of drug added –Amount of drug non encapsulated *100                    
i. Amount of drug loaded.  
 
 
 
Department of Life Science, NIT Rourkela  Page 30 
 
6. Determination of Drug release efficacy: 
Determination of drug release efficacy of  Drug loaded Gelatin NPs and liposomes 
can be determined by membrane study. Samples were placed  in a falcon tube, 
submerged in PBS solution in a beaker  and was subjected to constant stirring at 
300rpm at 37ºC. The PBS was changed every 1hr.,initially from 0.25hr to 12hrs. The 
drug release efficacy was determined by UV-Vis spectrophotometer (Perkin-Elmer, 
Lamda 35,Germany) at a wavelength of 254nm respectively. 
 
7. Hema-compatibility studies: 
 
a. Hemagglutination Assay: 
 
1ml blood sample was centrifuged in 2ml microtube at 1000 rpm for 5min at room temperature 
by eppendorf mini spin. Then the pellet was collected and to it 10ml of PBS was added . The 
mixture of blood and PBS was centrifuged at 1000 rpm for 5min at room temperature. After 
centrifugation the pellets was collected and from this 100l of pellet was taken and added 
to10ml of PBS solution (pH 7.2). The Haemagglutination activity of GNPs and Liposomal GNPs 
was detected when blood erythrocytes were added to it. The assay was carried out in a 96 well 
round bottom micro-titre plate. The first well of each row was served as positive control to which 
100l of normalized sample and 100l of blood was added and the last well served as negative 
control since it contained 100l of blood and 100l of PBS solution. Between the positive and 
negative control each well contains blood, PBS and sample. First of all 100l PBS was added to 
all the wells. Then 100l of sample was poured to the first well and it was serially diluted till the 
negative control. Similar procedure was followed for the other samples. Finally 100l of 
processed blood sample was poured to each well. After that the plate was placed in a plane 
surface without disturbing it. After 30mins the haemagglutination assay result was observed. 
 
b. Hemolysis: 
3% sodium citrate(anticoagulant) was added to 10ml of blood. Positive and negative control 
were prepared. Positive control contained 0.5ml of blood,0.5ml of 0.01NHCl and 9ml of 
saline water, whereas negative control contained 0.5ml of blood,9.5ml of saline water and 
that of sample (0.5g). The falcons with sample were incubated for 2hrs at 37ºC. The samples 
were then centrifuged for 20mins at 3000rpm. The % hemolysis was determined by UV-Vis 
spectrophotometer (Perkin-Elmer, Lamda 35,Germany) at a wavelength of 254nm. 
 
 
8. Cell Viability Study: MTT ASSAY 
To determine the proliferative activity, Hacat  and HEK cells were seeded in two 96-well 
plates at a density (5000-40,000 cells or 106 cells) based on the doubling time, with 200 μl 
growth media (10% FBS) and incubated for 24 hrs in incubator with 5% CO2 
concentration at 37ºC. Cell seeding must be uniform in order to obtain a dose response 
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effect of the drug. The samples were taken in different concentrations in the growth 
media. In parallel the cells with the solvent control was also treated to assess its effect on 
cells. After 24 hours existing media (DMEM) was removed and replaced with media with 
various concentration of sample and was incubated for 24 or 48 hours at 37o C. To detect 
the cell viability MTT working solution was prepared by diluting the stock solution (stock 
5mg/ml PBS, PH 7.2) in growth medium without FBS to the final concentration of 
0.8mg/ml.100 μl of MTT working solution was added to each well and incubated for 4 
hours in CO2 incubator. After incubation, the media was removed carefully. 
 
9.  Anti-microbial activity: 
Bacterial culture was inoculated into test tube containing Nutrient Broth (NB) and 
incubated at 28ᵒC for 2-3 days. 100 μl of the broth culture was added onto a slide and the 
slide was put in the prepared Nutrient Agar (NA) plates. Wells were punctured onto the 
agar plates and 100μl of various concentrations of samples were loaded into the wells and 
incubated for 3-4 days. After 3-4 days, the area in the plate with zone of inhibition was 
measured. 
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Gelatin Water Acetone Water Acetone Glutaral-
dehyde 
Total 
Volume 
50mg 10ml 10ml 10ml 30ml 60µl 50ml 
100mg 10ml 10ml 10ml 30ml 60µl 50ml 
200mg 10ml 10ml 10ml 30ml 60µl 50ml 
 
 
 
Gelatin Water Acetone Water Acetone Drug Glutaral-
Dehyde 
Total 
100mg 10ml 10ml 10ml 30ml 50mg  
(10ml) 
60µl 60ml 
100mg 10ml 10ml 10ml 30ml 25mg (10ml) 60µl 60ml 
100mg 10ml 10ml 10ml 30ml 10mg(10ml) 60µl 60ml 
100mg 10ml 10ml 10ml 30ml 5mg (10ml) 60µl 60ml 
 
 
 
Gelatin 100mg 100mg 100mg 100mg 
Drug 50mg 25mg 10mg 5mg 
RATIO 1:2 1:4 1:10 1:20 
 
 
 
 
Soy lecithin Ethanol Water Total Volume 
0.6g 10ml 5ml 15ml 
    
 
 
 
Soy lecithin 0.6g 0.6g 0.6g 
Ethanol 10ml 10ml 10ml 
Water 5ml 5ml 5ml 
Drug 1:2 1:4 1:10 
 
Table 1: Composition of  Blank Gelatin NPs- 
 
Table 2: Composition of  Drug loaded 100mg 
Gelatin NPs- 
 
Table 3: Drug loaded 100mg Gelatin NPs- 
 
Table 4.Composition of blank liposome: 
 
Table 5: Composition of liposomal drug loaded GNPs: 
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RESULTS AND 
DISCUSSION 
 
 
Department of Life Science, NIT Rourkela  Page 34 
 
The various formulations of drug loaded GNPs and Liposomal drug loaded GNPs were 
characterized and their results are shown below: 
 
SEM ANALYSIS: 
 
SEM provided further insight into the morphology and size details of the gelatin nanoparticles. 
Comparison of experimental results showed that the diameters of prepared nanoparticles in 
the solution have sizes of several μm in case of  1:4, 1:10, 1:20 ratios where as in 1:2 ratio the 
size is of several nm. . (Figure:2, Figure: 3, Figure: 4 & Figure: 5).. The result showed that 
the particles were of spherical shape in case 1:2 , 1:4 , 1:10 ,1:20 ratios. The various drug 
loaded formulations of drug loaded GNPs appeared more or less spherical when observed by 
SEM. 
 
                                      
      
 
 
Fig-5: 100 GNPs 
RESULTS TO BE PUBLISHED 
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Fig 6: 1:20 GNPs 
Fig 7: 1:10 GNPs 
RESULTS TO BE PUBLISHED 
RESULTS TO BE PUBLISHED 
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Fig 8: 1:4 GNPs 
Fig 9: 1:2 GNPs 
RESULTS TO BE PUBLISHED 
RESULTS TO BE PUBLISHED 
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XRD ANALYSIS:  
XRD spectrum (Figure: 6) showed distinct diffraction peaks around 38º. These sharp Bragg 
peaks might have resulted due to capping agent stabilizing the nanoparticle. Intense Bragg 
reflections suggest that strong X-ray scattering centres in the crystalline phase and could be 
due to capping agents. Independent crystallization of the capping agents was ruled out due to 
the process of centrifugation and redispersion of the pellet in millipore water after 
nanoparticles formation as a part of purification process. Therefore, XRD results also 
suggested that the crystallization of the bio-organic phase occurs on the surface of the gelatin 
nanoparticles or vice versa. Generally, the broadening of peaks in the XRD patterns of solids 
is attributed to particle size effects. Broader peaks signify smaller particle size and reflect the  
 
 
 
 
 
 
Fig 10: XRD result for different formulations of drug loaded GNPs 
 
RESULTS TO BE PUBLISHED 
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FTIR ANALYSIS: 
 
( 
 
 
Results to be published. 
 
RESULTS TO BE PUBLISHED 
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DLS AND ZETA: 
 
The zeta potential of the liposomal suspensions were mostly in the range of -43.4 mV to -30 mV 
which indicated good stability. But the zeta potential values of GNPs ranged between -2.2 mV to 
-29.0 mV indicating incipient stability. Similarly the size of GNPs and liposome lie in the range of 
300 – 350nm and 150-200 nm respectively. This value helps to determine whether the 
suspension is mono-dispersed or poly-dispersed. Generally if the PDI value lies between 0.00-
0.5. the suspension is considered mono-dispersed, while PDI values greater than 0.5 indicates 
poly-dispersed suspension.  
Fig 12- FTIR of Liposomes 
 
RESULTS TO BE PUBLISHED 
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ENCAPSULATION EFFICIENCY: 
 
The graph showed better encapsulation by liposomes as compared to GNPs in each 
concentration range. This may be due to better solubility of the drug with liposome. 
Moreover higher the concentration of drug solution used higher was the encapsulation 
efficiency.  
Our results showing higher encapsulation efficiency and stability in case of Liposomal 
formulations is in compliance with results of other research groups (Dubey et al., 2007). High 
encapsulation efficiency and stability is due to better solubility and retentivity of the drug 
Stavudine in ethanol (Touitou et al., 2000) 
Fig 14:  Size of Liposomes 
Fig 16:   Charge of Liposomes 
              
RESULTS TO BE PUBLISHED 
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PUBLISHED 
RESULTS TO BE PUBLISHED 
Fig 13:   Size of GNPs 
Fig 16:   Charge of GNPs 
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DRUG RELEASE: 
 The drug release of Drug loaded GNPs and Liposomes were studied which showed us- 
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Fig 18:   Standard curve of the drug Fig 17 : Encapsulation Efficiency for 
Liposomes  and GNPs 
Results to be published 
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Fig 20: Drug release in  Liposomes 
Fig 19:  Drug release in GNPs 
Results to be published 
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Hemacompatibility: 
 
a) Hemagglutination- 
 
 
Fig 21: Hemagglutination in Liposomes and 
GNPs 
Results to be published 
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b) Hemolysis: 
 
 
  
 
 
Fig 22: Hemagglutination in Blank 
Samples 
Fig 23: Hemolysis of GNPs Fig 24: Hemolysis of Liposomes 
Results to be published 
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Cell Viability: 
 
MTT ASSAY: 
 
 
 
 
 
 
 
   
 
                                                                   
 
 
 
 
Fig 25: Hemolysis of different samples 
Fig 26: Cell viability study  of GNPs in 
HaCat Cell line 
  
Fig 27: Cell viability study  of Liposomes in 
HaCat Cell line 
Results to be published 
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Anti-microbial studies: 
 
 
 
                 
 
 
 
 
              
 
 
 
 
 
 
 
 
Fig 29: Anti-microbial in   Pseudomonas Sp. 
Fig 28: Anti- microbial activity in  Bacillus 
sp. 
RESULTS TO BE PUBLISHED 
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From the above work so done, we can finally conclude that the Gelatin NPs have  better size 
and charge and they can be used for the drug delivery systems, where gelatin can be used as 
adjuvants. Also gelatin can cross th blood brain barrier thus moving inside the cells 
promising a better result. The liposomal conjugated NPs can also prove to better drug 
delivery option because liposomes can pass through the cells and they can stay in the body 
for a longer period of time than that compared to GNPs. The drug Stavudine conjugated with 
Liposomes and Gelatin NPs can improve the longevity of the HIV patient,leading to a better 
life. Thus,it can be concluded that GNPs loaded Stavudine when incorporated into our body 
works in a better way than that of blank Gelatin NPs and Liposomes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
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